HSBC Holdings
PGNX

HSBC Holdings’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

HSBC Holdings’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,940
Closed -$112K – 2746
2016
Q4 		$112K Buy
+12,940
New +$95.6K ﹤0.01% 2610

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

HSBC Holdings's PGNX Position: Q1 2017 in Review

HSBC Holdings sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2017, closing a stake of 12,940 shares — an estimated $112K sold.

HSBC Holdings first reported a position in PGNX in Q4 2016 and held it in 1 quarter. The position peaked at $112K in Q4 2016. 159 funds tracked by Wall St. Rank hold PGNX as of Q1 2017.

  • HSBC Holdings reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • HSBC Holdings sold 12,940 Progenics Pharmaceuticals Inc shares in Q1 2017, an estimated $112K.
  • HSBC Holdings first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 1 quarter.
  • HSBC Holdings's Progenics Pharmaceuticals Inc position peaked at $112K in Q4 2016.
  • 159 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2017.

Based on HSBC Holdings's 13F filing for Q1 2017, filed 15 May 2017.